全文获取类型
收费全文 | 46587篇 |
免费 | 3694篇 |
国内免费 | 1926篇 |
专业分类
耳鼻咽喉 | 168篇 |
儿科学 | 827篇 |
妇产科学 | 490篇 |
基础医学 | 6721篇 |
口腔科学 | 509篇 |
临床医学 | 3666篇 |
内科学 | 13196篇 |
皮肤病学 | 640篇 |
神经病学 | 3102篇 |
特种医学 | 907篇 |
外国民族医学 | 2篇 |
外科学 | 3675篇 |
综合类 | 5197篇 |
现状与发展 | 5篇 |
预防医学 | 2700篇 |
眼科学 | 864篇 |
药学 | 6082篇 |
6篇 | |
中国医学 | 1513篇 |
肿瘤学 | 1937篇 |
出版年
2023年 | 440篇 |
2022年 | 597篇 |
2021年 | 1075篇 |
2020年 | 1148篇 |
2019年 | 1821篇 |
2018年 | 1792篇 |
2017年 | 1613篇 |
2016年 | 1586篇 |
2015年 | 1749篇 |
2014年 | 2859篇 |
2013年 | 3308篇 |
2012年 | 2614篇 |
2011年 | 2901篇 |
2010年 | 2178篇 |
2009年 | 2114篇 |
2008年 | 2096篇 |
2007年 | 2305篇 |
2006年 | 2028篇 |
2005年 | 1781篇 |
2004年 | 1564篇 |
2003年 | 1444篇 |
2002年 | 1218篇 |
2001年 | 1091篇 |
2000年 | 927篇 |
1999年 | 822篇 |
1998年 | 659篇 |
1997年 | 701篇 |
1996年 | 520篇 |
1995年 | 576篇 |
1994年 | 502篇 |
1993年 | 380篇 |
1992年 | 335篇 |
1991年 | 261篇 |
1990年 | 201篇 |
1989年 | 179篇 |
1988年 | 150篇 |
1987年 | 131篇 |
1985年 | 466篇 |
1984年 | 565篇 |
1983年 | 453篇 |
1982年 | 418篇 |
1981年 | 406篇 |
1980年 | 363篇 |
1979年 | 324篇 |
1978年 | 276篇 |
1977年 | 208篇 |
1976年 | 247篇 |
1975年 | 250篇 |
1974年 | 196篇 |
1973年 | 174篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
101.
102.
目的 探讨IgG4和C3在泪腺良性淋巴上皮病变发生发展中的作用。方法 收集2010年7月至2018年5月就诊于承德医学院附属医院眼科、解放军总医院眼科15例(15眼)泪腺良性淋巴上皮病变患者的泪腺肿物为试验组,10例(10眼)因其他疾病而行眶内容物摘除术的正常泪腺组织标本为对照组。采用HE染色法观察2组泪腺病理形态学变化及其组织病理学特点,采用免疫组织化学染色法检测2组泪腺组织中IgG4、C3的表达,并对二者表达相关性进行分析。结果 HE染色结果显示,对照组泪腺由正常腺泡及导管组成,导管上皮细胞排列整齐,细胞结构清晰,其间有少量的淋巴细胞;试验组泪腺组织中可见大量淋巴细胞、浆细胞浸润,淋巴滤泡形成,其间可见上皮-肌上皮岛结构改变,同时伴有不同程度纤维化。IgG4在试验组阳性表达面积为(30 934.80±16 057.17)像素,对照组阳性表达面积为(325.42±204.43)像素,试验组中明显高于对照组(t=-7.38,P=0.000);C3在试验组阳性表达面积为(43 169.49±33 206.60)像素,对照组阳性表达面积为(323.24±271.29)像素,试验组中明显高于对照组,差异有统计学意义(t=-5.00,P=0.000)。试验组中IgG4与C3表达无相关性(r=-0.137,P=0.671)。结论 泪腺良性淋巴上皮病变患者的泪腺发生了明确的病理改变,这可能与IgG4和C3在泪腺中的高表达有关。 相似文献
103.
目的:分析CYP2C19*3基因多态性与癫痫患者奥卡西平(oxcarbazepine,OXC)活性代谢产物10,11-二氢-10-羟基卡马西平(monohydroxycarbazepine,MHD)血药浓度的相关性。方法:纳入120例OXC单药治疗1个月以上且症状控制良好的癫痫患者,采集清晨服药前空腹血,采用高效液相色谱法测定MHD稳态谷浓度。通过PCR和sanger测序判定患者CYP2C19*3基因型。结果:120例癫痫患者快代谢患者64例,MHD血浆浓度为(18.17±7.34)μg·mL-1;中代谢型患者36例,MHD血浆浓度为(19.31±9.17)μg·mL-1;慢代谢型患者20例,MHD血浆浓度为(25.79±7.51)μg·mL-1,3种基因型的MHD浓度有显著性差异(F=7.077,P=0.0013)。多因素分析显示,日剂量作为影响血药浓度的重要指标呈现出显著相关性(P<0.05)。结论:CYP2C19*3基因多态性影响MHD血药浓度,并且日剂量越高,MHD血药浓度越大,两者成显著正相关,临床应进行血药浓度监测。 相似文献
104.
Andreu Porta-Sánchez Andrew C.T. Ha Xuesong Wang Fahad Almehmadi Peter C. Austin Hadas D. Fischer Atif Al-Qubbany Diego Chemello Vijay Chauhan Eugene Downar Douglas S. Lee Kumaraswamy Nanthakumar 《The Canadian journal of cardiology》2019,35(2):169-177
Background
Catheter ablation of ventricular tachycardia (VT) can reduce the burden of ventricular arrhythmia (VA) but its effect on health care utilization and costs after such therapy is poorly known. We sought to compare the rates of cardiovascular (CV)-related hospitalizations, survival, and health care costs in patients with recurrent VT treated either with VT ablation or with medical therapy.Methods
One-hundred implantable cardioverter-defibrillator patients with structural heart disease who underwent VT ablation were included. Propensity score-matched patients with recurrent VT treated with medical therapy were identified from a prospective registry of approximately 7000 de novo implantable cardioverter-defibrillator patients. Outcomes and costs were ascertained using health administrative databases.Results
Among patients who underwent VT ablation, the cumulative rates of VA-related hospitalizations were lower in the 2 years after their ablation procedure compared with the year before (rate ratio, 0.3; 95% confidence interval [CI], 0.22-0.43). Rates of CV-related hospitalization and hospitalization because of VA post index date were similar between the VT ablation and medical therapy groups (hazard ratio [HR], 0.94; 95% CI, 0.57-1.54 and HR, 1.04; 95% CI, 0.57-1.91, respectively). Health care costs in the VT ablation patients were not increased post-ablation compared with the medical management group. The risk of all-cause mortality was lower among patients in the VT ablation group relative to the medical therapy group (HR, 0.64; 95% CI, 0.4-0.99).Conclusions
Patients who underwent VT ablation experienced a significant reduction in their rate of VA-related hospitalizations. Patients treated with VT ablation had similar rates of CV-related hospitalization compared with those treated with medical therapy without increased health care-related costs. 相似文献105.
François-Pierre Mongeon Laurent Macle Luc M. Beauchesne Berto J. Bouma Markus Schwerzmann Barbara J.M. Mulder Paul Khairy 《The Canadian journal of cardiology》2019,35(12):1686-1697
Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have several advantages over VKAs that render them an attractive option for adults with congenital heart disease (CHD). Efficacy and safety data specific to the adult CHD population are emerging. Herein, we synthesize the growing literature regarding NOACs in adults with CHD and attempt to identify subgroups for which it appears reasonable to extrapolate data from populations without CHD. Small observational studies suggest that NOACs are safe and effective in selected adults with CHD. NOACs are contraindicated in patients with a mechanical valve, in those with mitral or tricuspid valve stenosis with enlarged and diseased atria, with or without a mitral or tricuspid bioprosthesis, and after recent cardiac surgery (< 3 months). There is currently insufficient evidence to recommend NOACs in patients with a Fontan circulation or cyanotic CHD. Growing literature supports the use of NOACs in patients without CHD who have various forms of valvular heart disease. Therefore, when an indication for oral anticoagulation is established, it appears reasonable to consider a NOAC instead of a VKA in adults with CHD lesions analogous to isolated mitral regurgitation, tricuspid regurgitation, or aortic regurgitation or stenosis. The NOAC agent selected and the prescribed dose should be tailored according to bleeding risk, body weight, renal function, and comedications, especially antiepileptic drugs. The decision to initiate a NOAC should be shared between the patient and care provider. Large-scale research studies are required to further assess safety and efficacy in selected patient subgroups. 相似文献
106.
107.
目的 发现有抗菌活性或是增效活性的银杏酸C17:1衍生物。方法 以银杏酸C17:1为底物,利用一些基团取代苯环上的羧基从而获得银杏酸C17:1衍生物,棋盘法设计试验,测定银杏酸C17:1及其衍生物联合抗生素的增效作用,通过测定Zeta电位、ROS、NPN吸收来探究增效机制。结果 银杏酸C17:1衍生物Ⅱ与达托霉素联合抗粪肠球菌的部分抑菌浓度指数(FICIs)为0.125~0.25,具有明显的协同效应,不仅能产生较高的活性氧,而且能在一定程度改变细胞膜的通透性。结论 银杏酸衍生物Ⅱ对达托霉素体外抗耐药株具有较好的增效作用,可能和ROS的激增以及膜通透性的改变有关。 相似文献
108.
109.
110.
Graziana Gallo Heinz Kutzner Thomas Mentzel Anna M. Cesinaro 《Journal of cutaneous pathology》2019,46(1):80-83
Cellular neurothekeoma (CNT) is a dermal lesion with still unknown histogenesis, characterized by immunohistochemical staining for NKI/C3, NSE, MiTF, CD10 and CD68, whereas S100 protein, desmin and cytokeratins are negative. Particularly, in several studies NKI/C3 has been reported as a strong marker of CNT. We describe herein the clinical, histopathological and immunohistochemical features of two cases morphologically consistent with myxoid CNT, one of which showing some atypical features, both characterized by negative immunohistochemical staining for NKI/C3. Our findings stress the importance of morphology in diagnosing CNT and underline the fact that NKI/C3 can fail to stain cases belonging to the “neurothekeoma family.” In selected cases of CNT, an expanded immunohistochemical panel is mandatory to differentiate this tumor from other dermal lesions. 相似文献